Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts

Hemab Therapeutics is building a differentiated coagulation franchise targeting underserved rare bleeding disorders with a prophylactic approach. COAG's robust cash position post-IPO funds operations into 2029, supporting multiple clinical catalysts across sutacimig, HMB-002, and preclinical HMB-003. Lead asset sutacimig shows strong Phase 2 efficacy and FDA-aligned Phase 3 dosing, while HMB-002 and HMB-003 broaden addressable markets. I am bullish as Hemab's pipeline offers multiple shots on goal, favorable market positioning, and compelling orphan/large market expansion potential.

I am bullish about Hemab Therapeutics (COAG) because I believe the company is being viewed far too narrowly (as just another newly public rare-disease biotech), whereas a better way to look at it would be